Review
Multidisciplinary Sciences
Andre Eduardo de Almeida Franzoi, Fernanda Subtil de Moraes Machado, Washigton Luiz Gomes de Medeiros Junior, Isabelle Pastor Bandeira, Wesley Nogueira Brandao, Marcus Vinicius Magno Goncalves
Summary: miRNAs play crucial roles in MS by regulating gene expression in various cells. NTZ treatment modifies gene expression and miRNA levels in B cells, indicating a potential for specific miRNAs to serve as markers of therapeutic response in MS patients. Understanding the complex interaction between miRNAs, gene expression in B cells, and therapeutic response is important for MS treatment.
Article
Behavioral Sciences
Arwa Rekik, Mona Aissi, Islem Rekik, Mariem Mhiri, Mahbouba Ayed Frih
Summary: In patients with multiple sclerosis (MS), treatment with natalizumab (NTZ) can reduce brain atrophy, particularly targeting highly cognitive regions. The progression of brain atrophy is correlated with memory impairment and physical disability.
BRAIN AND BEHAVIOR
(2022)
Article
Biochemistry & Molecular Biology
Flora Reverchon, Colleen Guillard, Lucile Mollet, Pascal Auzou, David Gosset, Fahima Madouri, Antoine Valery, Arnaud Menuet, Canan Ozsancak, Maud Pallix-Guyot, Severine Morisset-Lopez
Summary: This study reveals a dysregulation of 5-HT7 expression in natalizumab-treated multiple sclerosis (MS) patients, with an increase in 5-HT7 surface expression on T lymphocytes and CD4(+) T cell subsets. Activation of 5-HT7 receptor promotes the production of IL-10, suggesting its protective role in MS.
Article
Clinical Neurology
Chao Zhu, Zhen Zhou, Izanne Roos, Daniel Merlo, Tomas Kalincik, Serkan Ozakbas, Olga Skibina, Jens Kuhle, Suzanne Hodgkinson, Cavit Boz, Raed Alroughani, Jeannette Lechner-Scott, Michael Barnett, Guillermo Izquierdo, Alexandre Prat, Dana Horakova, Eva Kubala Havrdova, Richard Macdonell, Francesco Patti, Samia Joseph Khoury, Mark Slee, Rana Karabudak, Marco Onofrj, Vincent Van Pesch, Julie Prevost, Mastura Monif, Vilija Jokubaitis, Anneke van der Walt, Helmut Butzkueven
Summary: Ocrelizumab and natalizumab are more effective than cladribine in reducing relapses in patients with relapsing-remitting multiple sclerosis switching from fingolimod. Additional observation time is needed to determine if the statistical difference in annualized relapse rate (ARR) results in long-term disability differences.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
(2022)
Article
Clinical Neurology
Kevin Bigaut, Laurent Kremer, Thibaut Fabacher, Guido Ahle, Mathilde Goudot, Marie Fleury, Claude Gaultier, Sylvie Courtois, Nicolas Collongues, Jerome de Seze
Summary: This study compared the effectiveness of ocrelizumab and fingolimod after natalizumab cessation. The results showed that ocrelizumab had a significantly lower relapse rate at 1 year compared to fingolimod.
JOURNAL OF NEUROLOGY
(2022)
Article
Immunology
Emanuele D'Amico, Aurora Zanghi, Nunziatina Laura Parrinello, Alessandra Romano, Giuseppe Alberto Palumbo, Clara Grazia Chisari, Simona Toscano, Francesco Di Raimondo, Mario Zappia, Francesco Patti
Summary: This study characterized the immune cell phenotypes of patients recently diagnosed with relapsing-remitting multiple sclerosis who had not received disease-modifying therapies. The results revealed differences in myeloid, B, and T cells between these patients and healthy controls.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Clinical Neurology
Alyssa A. Toorop, Zoe L. E. van Kempen, Maurice Steenhuis, Jessica Nielsen, L. G. F. Sinnige, Gert van Dijk, Christiaan M. Roosendaal, Edo P. J. Arnoldus, Elske Hoitsma, Birgit Lissenberg-Witte, Brigit A. de Jong, Bob W. van Oosten, Eva M. M. Strijbis, Bernard M. J. Uitdehaag, Theo Rispens, Joep Killestein
Summary: The study evaluated the change in natalizumab trough drug levels when switching from intravenous to subcutaneous administration. It was found that the drug levels were on average 55% lower with subcutaneous administration, leading to very low levels in some patients. Monitoring of trough drug levels is advised when switching to subcutaneous administration in patients with low intravenous drug levels, higher body mass index, or extended treatment intervals.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
(2023)
Article
Virology
Simone Agostini, Roberta Mancuso, Andrea Saul Costa, Domenico Caputo, Mario Clerici
Summary: The detection of miR-J1-5p in urine of MS patients treated with Natalizumab could potentially serve as a biomarker to monitor JCPyV infection and better identify the risk of developing PML. The study found miR-J1-5p in the urine of 28% of patients, even in some cases where JCPyV DNA was not detected in urine or blood. This suggests that miR-J1-5p measurement could be valuable in assessing PML risk in Natalizumab-treated MS patients.
Article
Medicine, General & Internal
Daria M. Potashnikova, Aleena A. Saidova, Anna V. Tvorogova, Alexandra S. Anisimova, Alexandra Yu Botsina, Elena Yu Vasilieva, Leonid B. Margolis
Summary: The study found that the presence of fibronectin can significantly increase CTL adhesiveness in atherosclerosis patients, and the expression levels of integrin-coding mRNAs also increase accordingly.
FRONTIERS IN MEDICINE
(2022)
Article
Pharmacology & Pharmacy
Rong-Hong Guo, Hao Cheng, Xiao-Ying Zhang, Zhen Yu, Guang-Hui Wang, Shu-Ya Hao, Xiao-Peng Gao, Hong-Yan Wen
Summary: This study aimed to investigate the changes in absolute numbers of T-lymphocyte subsets and serum cytokines in patients with systemic sclerosis (SSc). The study found that patients with SSc had lower numbers of Th2 and Treg cells compared to healthy controls, which led to significantly increased ratios of Th1/Th2 and Th17/Treg. Additionally, the levels of certain cytokines were significantly higher in SSc patients. The findings contribute to a better understanding of the pathogenesis of SSc and provide a basis for the development of novel therapeutic interventions targeting these cells and cytokines.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Medicine, General & Internal
Ranjani Ganapathy Subramanian, Dana Horakova, Manuela Vaneckova, Balazs Lorincz, Jan Krasensky, Eva Kubala Havrdova, Tomas Uher
Summary: The study found that natalizumab treatment can reduce inflammatory markers in the cerebrospinal fluid of multiple sclerosis patients, decrease the levels of white blood cells and proteins, as well as the number of oligoclonal bands in the cerebrospinal fluid. Additionally, the baseline IgM index was found to predict brain volume loss during natalizumab treatment.
Article
Clinical Neurology
Marco Puthenparampil, Marta Gaggiola, Alessandro Miscioscia, Valentina Annamaria Mauceri, Federica De Napoli, Giovanni Zanotelli, Mariagiulia Anglani, Margherita Nosadini, Stefano Sartori, Paola Perini, Francesca Rinaldi, Paolo Gallo
Summary: This study evaluated the efficacy and safety of alemtuzumab (ALZ) in pediatric-onset multiple sclerosis (POMS) and adult-onset multiple sclerosis (AOMS) patients undergoing treatment switch. The results showed that ALZ was more effective in AOMS patients compared to POMS patients after switching from natalizumab (NTZ). However, these findings may underestimate the effectiveness of ALZ in POMS patients.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS
(2023)
Article
Clinical Neurology
Alyssa A. Toorop, Zoe Y. G. J. van Lierop, Liza M. Y. Gelissen, Elske Hoitsma, Esther M. P. E. Zeinstra, Luuk C. van Rooij, Caspar E. P. van Munster, Anke Vennegoor, Jop P. Mostert, Beatrijs H. A. Wokke, Nynke F. Kalkers, Erwin L. J. Hoogervorst, Jeroen J. J. van Eijk, Christiaan M. Roosendaal, Jolijn J. Kragt, Marijke Eurelings, Jessie van Genugten, Jessica Nielsen, Lgf Sinnige, Mark E. Kloosterziel, Edo P. J. Arnoldus, Gert W. van Dijk, Willem H. Bouvy, Mark H. J. Wessels, Lynn Boonkamp, Eva M. M. Strijbis, Bob W. van Oosten, Brigit A. De Jong, Birgit Lissenberg-Witte, Frederik Barkhof, Bastiaan Moraal, Charlotte E. Teunissen, Theo Rispens, Bernard M. J. Uitdehaag, Joep Killestein, Zoe L. E. van Kempen
Summary: Personalized extended interval dosing of natalizumab effectively controls disease activity in multiple sclerosis and can safely extend treatment intervals through therapeutic drug monitoring.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
(2023)
Article
Clinical Neurology
Eva M. Strijbis, Eline Coerver, Jop Mostert, Zoe L. E. van Kempen, Joep Killestein, Jacynthe Comtois, Pavle Repovic, James D. Bowen, Gary Cutter, Marcus Koch
Summary: This study investigates the association between age and inflammatory disease activity in relapsing-remitting multiple sclerosis (RRMS) using patient-level data from randomized controlled trials (RCTs) of natalizumab treatment. The results show that older age is associated with lower prevalence and degree of focal inflammatory disease activity in treated and untreated RRMS patients. These findings provide important insights for the design of RCTs and the decision-making process of immunomodulatory treatment in RRMS.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
(2023)
Article
Clinical Neurology
Doriana Landi, Francesca Bovis, Alfonso Grimaldi, Pietro Osvaldo Annovazzi, Antonio Bertolotto, Alessia Bianchi, Giovanna Borriello, Vincenzo Brescia Morra, Sebastiano Bucello, Maria Chiara Buscarinu, Francesca Caleri, Marco Capobianco, Ruggero Capra, Maria Cellerino, Diego Centonze, Raffaella Cerqua, Clara Grazia Chisari, Marinella Clerico, Eleonora Cocco, Gaia Cola, Cinzia Cordioli, Erica Curti, Alessandro d'Ambrosio, Emanuele D'Amico, Giovanna De Luca, Massimiliano Di Filippo, Sonia Di Lemme, Roberta Fantozzi, Diana Ferraro, Elisabetta Ferraro, Antonio Gallo, Claudio Gasperini, Franco Granella, Matilde Inglese, Roberta Lanzillo, Lorena Lorefice, Giacomo Lus, Simona Malucchi, Monica Margoni, Giorgia Mataluni, Massimiliano Mirabella, Lucia Moiola, Carolina Gabri Nicoletti, Viviana Nociti, Francesco Patti, Federica Pinardi, Emilio Portaccio, Carlo Pozzilli, Paolo Ragonese, Sarah Rasia, Giuseppe Salemi, Elisabetta Signoriello, Francesca Vitetta, Rocco Totaro, Maria Pia Sormani, Maria Pia Amato, Girolama Alessandra Marfia
Summary: The study found that continuing natalizumab treatment throughout pregnancy and resuming it early after delivery can reduce the risk of clinical and radiological reactivation in women with multiple sclerosis. This approach has no major impact on newborns' outcomes.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
(2022)
Article
Health Care Sciences & Services
Clemens Huettenbrink, Wolfgang Hitzl, Sascha Pahernik, Jens Kubitz, Valentin Popeneciu, Jascha Ell
Summary: This study aimed to develop prediction models for ureterorenoscopy using machine learning techniques. The models were trained and tested using CT imaging data and patient information to predict the need for laser lithotripsy and the expected duration of the surgery. The predictions can help optimize surgical planning and resource allocation, improving efficiency in the operating room.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Article
Clinical Neurology
Gabriel Bsteh, Hamid Assar, Christiane Gradl, Bettina Heschl, Maria-Sophie Hiller, Nik Krajnc, Franziska Di Pauli, Harald Hegen, Gerhard Traxler, Fritz Leutmezer, Peter Wipfler, Gudrun Zulehner, Michael Guger, Christian Enzinger, Thomas Berger
Summary: The long-term outcome of COVID-19 in pwMS is favorable, with the majority of patients experiencing complete recovery and only a small proportion suffering from persistent symptoms. COVID-19 does not increase the risk of relapse or disability in pwMS.
EUROPEAN JOURNAL OF NEUROLOGY
(2022)
Article
Biochemistry & Molecular Biology
Fabian Foettinger, Georg Pilz, Peter Wipfler, Andrea Harrer, Jan Marco Kern, Eugen Trinka, Tobias Moser
Summary: Therapeutic plasma exchange (TPE) is used for drug-resistant neuroimmunological disorders, but its mechanism of action remains poorly understood. This study investigated changes in immune components associated with TPE and found that pathogen-specific antibody levels were reduced post-TPE and recovered during follow-ups. Ig subclasses were also reduced post-TPE and showed subsequent recovery. IL-6 and CRP concentrations increased post-TPE, while no alterations were found in B- and T-cell populations.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Biochemistry & Molecular Biology
Michael Seiberl, Julia Feige, Patrick Hilpold, Wolfgang Hitzl, Lukas Machegger, Arabella Buchmann, Michael Khalil, Eugen Trinka, Andrea Harrer, Peter Wipfler, Tobias Moser
Summary: This study investigated the impact of cladribine on serum neurofilament light chain (sNfL) and its potential as a predictor of long-term treatment response. The results showed that cladribine significantly reduced sNfL levels, but baseline and 12-month sNfL assessments failed to predict clinical and radiological treatment response.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Medicine, General & Internal
Julia Hanne Niebauer, Christina Binder-Rodriguez, Ahmet Iscel, Sarah Schedl, Christophe Capelle, Michael Kahr, Simona Cadjo, Simon Schamilow, Roza Badr-Eslam, Michael Lichtenauer, Aurel Toma, Alexander Zoufaly, Rosmarie Valenta, Sabine Hoffmann, Silvia Charwat-Resl, Christian Krestan, Wolfgang Hitzl, Christoph Wenisch, Diana Bonderman
Summary: We aimed to identify the long-term cardiopulmonary effects of severe COVID-19 disease and the predictors of Long-COVID. A prospective registry included 150 hospitalized patients who were followed up six months after discharge. The study found that a majority of patients fulfilled the criteria for Long-COVID, and various cardiopulmonary abnormalities were detected, including impaired pulmonary function, reduced GLS, and diastolic dysfunction. Predictors of Long-COVID included length of in-hospital stay, admission to the intensive care unit, and higher NT-proBNP levels.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Health Care Sciences & Services
Clemens Huettenbrink, Wolfgang Hitzl, Florian Distler, Jascha Ell, Josefin Ammon, Sascha Pahernik
Summary: The prediction of radiation exposure is crucial for therapy modality selection and informed consent. Implementing a trained machine learning model in a real-time computer system allows surgeons and patients to assess personal radiation risk. Factors influencing radiation exposure include age, gender, weight, stone size, surgeon experience, number of stones, stone density, use of flexible endoscope, and preoperative stone position.
JOURNAL OF PERSONALIZED MEDICINE
(2023)
Article
Health Care Sciences & Services
Kim Loose, Sophie Pennekamp, Wolfgang Hitzl, Maximilian Willauschus, Johannes Ruether, Sandeep Silawal, Philipp Schuster, Hermann Josef Bail, Michael Millrose, Markus Gesslein
Summary: In this retrospective study, patients with patellar tendinopathy (PT) were compared with a control group in terms of patient data and MRI characteristics. The study found significant differences in patellar height and patella-patellar tendon angle between the PT patient group and the control group. The thickness of different parts of the patellar tendon was also significantly increased in patients with PT. Persistence of symptoms over 6 months was associated with increased signal intensity in MRI. These findings can help in understanding PT and identifying suitable surgical candidates.
JOURNAL OF PERSONALIZED MEDICINE
(2023)
Article
Clinical Neurology
Kateriine Orav, Pilar Bosque Varela, Tanja Pruewasser, Lukas Machegger, Markus Leitinger, Eugen Trinka, Giorgi Kuchukhidze
Summary: The clinical outcome of patients with possible and definitive post-hypoxic status epilepticus was evaluated in this study. The study also aimed to describe the types of status epilepticus observed in patients with definitive post-hypoxic status epilepticus. The results showed a poor prognosis for patients with possible or definitive status epilepticus due to hypoxic brain injury.
EPILEPTIC DISORDERS
(2023)
Article
Dermatology
Ralph Bertram, Hans-Theodor Naumann, Vanessa Bartsch, Wolfgang Hitzl, Martina Kinzig, Golo-Sung Haarmeyer, Matthias Baumgaertel, Arnim Geise, Dorothea Muschner, Jens Nentwich, Stefan John, Fritz Soergel, Joerg Steinmann, Rainer Hoehl
Summary: This study aimed to determine the plasma concentrations of isavuconazole in ICU patients with COVID-19 and invasive fungal infection, and evaluate the factors contributing to sub-therapeutic drug levels. The results showed that patients' risk factors and supportive therapies can negatively affect the plasma levels of isavuconazole.
Article
Medicine, General & Internal
Francesco Pollari, Wolfgang Hitzl, Magnus Rottmann, Ferdinand Vogt, Miroslaw Ledwon, Christian Langhammer, Dennis Eckner, Juergen Jessl, Thomas Bertsch, Matthias Pauschinger, Theodor Fischlein, Omer Dzemali
Summary: This study used various machine learning models to predict the 1-year survival of patients undergoing transcatheter aortic valve implantation (TAVI). The models showed good predictive power and high accuracy in determining patients' survival rates.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Clinical Neurology
Laura Schnetzer, Verena S. Schaetzle, Lisa Kronbichler, Juergen Bergmann, Stefan Leis, Alexander B. Kunz, Julia S. Crone, Eugen Trinka, Martin Kronbichler
Summary: Diagnosing patients with disorders of consciousness can be prone to misdiagnosis. This study aims to determine the proportion of patients who display covert command following and evaluate the prognostic value of improved diagnosis. The researchers used functional MRI and a motor imagery task to identify patients with cognitive motor dissociation. The results showed that some patients exhibited covert command following, while others showed increased brain activation during rest. Additionally, 40% of patients showed significant activations in the whole brain analysis.
ACTA NEUROLOGICA SCANDINAVICA
(2023)
Article
Clinical Neurology
Eugen Trinka, Rodrigo Rocamora, Joao Chaves, Mathias J. Koepp, Stephan Rueegg, Martin Holtkamp, Joana Moreira, Miguel M. Fonseca, Guillermo Castilla-Fernandez, Fabio Ikedo
Summary: In patients with newly diagnosed focal epilepsy, monotherapy with ESL was associated with a lower proportion of increased plasma total cholesterol and LDL cholesterol compared to CBZ-CR. Switching from CBZ-CR to ESL resulted in a significant decrease in the proportion of patients with increased levels of cholesterol.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS
(2023)